Gary J. Grover - Concepedia

Author

Gary J. Grover

Also Known As

G J Grover, GARY J. GROVER, Gary Grover, Gary J Grover, Gary J. Grover, Gary James Grover, Grover, Gary J., Kenneth E. Dickinson, Paul Sleph

122

Publications

5.9K

Citations

H-Index

106

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Johnson University Bristol-Myers Squibb (Sweden)Eurofins (United States)

About

Gary J. Grover is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	52	2.8K
2	Health Sciences	11	14	840
3	Natural Sciences	11	11	491
4	Engineering	1	1	12
5	Public Health	1	1	20

Gary J. Grover

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Cardioprotective Effect of Diazoxide and Its Interaction With Mitochondrial ATP-Sensitive K<sup>+</sup>Channels Keith Garlid, Petr Pauček, Vladimir Yarov‐Yarovoy, Circulation Research	1997	1K
The Thyroid Hormone Receptor-β-Selective Agonist GC-1 Differentially Affects Plasma Lipids and Cardiac Activity<sup>1</sup> Susanne U. Trost, Eric A. Swanson, Bernd Gloss, Endocrinology	2000	272
Pharmacologic Profile of the Dihydropyrimidine Calcium Channel Blockers SQ 32,547 and SQ 32,946 Gary J. Grover, Steven Dzwonczyk, Diane M. McMullen, Journal of Cardiovascular Pharmacology Molecular PharmacologyCardiovascular DiseaseMedicinePhysiologySq 32,547	1995	256
Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability Gary J. Grover, Karin Mellström, Ye Liu, Proceedings of the National Academy of Sciences	2003	222
Effects of the Thyroid Hormone Receptor Agonist GC-1 on Metabolic Rate and Cholesterol in Rats and Primates: Selective Actions Relative to 3,5,3′-Triiodo-<scp>l</scp>-Thyronine Gary J. Grover, Donald Egan, Paul G. Sleph, Endocrinology Metabolic RateObesityMolecular PharmacologyMetabolic SyndromeSelective Actions	2004	162
Cardioprotection with the KATP Opener Cromakalim Is Not Correlated with Ischemic Myocardial Action Potential Duration Gary J. Grover, Albert J. DʼAlonzo, Charles S. Parham, Journal of Cardiovascular Pharmacology	1995	145
Thyroid Receptor Ligands. 1. Agonist Ligands Selective for the Thyroid Receptor β<sub>1</sub> Ye Liu, Yilin Li, Karin Mellström, Journal of Medicinal Chemistry Ligands SelectiveMolecular PharmacologyChain LengthIodine Deficiency DisordersParathyroid Hormone	2003	140
The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs Gary J. Grover, Steven Dzwonczyk, Charles S. Parham, Cardiovascular Drugs and Therapy Heart FailureCardiogenic ShockAnesthetized DogsCardiovascular DiseaseReperfusion Injury	1990	134
Pharmacological and X-Ray Structural Characterization of a Novel Selective Androgen Receptor Modulator: Potent Hyperanabolic Stimulation of Skeletal Muscle with Hypostimulation of Prostate in Rats Jacek Ostrowski, Joyce E. Kuhns, John A. Lupisella, Endocrinology Observed Tissue SelectivityPharmacotherapyPotent Hyperanabolic StimulationSkeletal MusclePotent Oral Activity	2006	129
Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F<sub>1</sub>F<sub>0</sub>-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity Gary J. Grover, Karnail S. Atwal, Paul G. Sleph, American Journal of Physiology-Heart and Circulatory Physiology Cardiac MuscleExcessive Atp HydrolysisMitochondrial BiologyMetabolic RemodelingRedox Biology	2004	115

Page 1